Table 4.

Association between troponin elevation and study endpoints by coronary artery disease and diabetes status

Pre-discharge (baseline) troponin I
Endpoint(12 months)	Subgroup	Adjusted HR (95% CI)	P for interaction
ACM	CAD	1.36 (0.99–1.87)	0.737
	Non-CAD	1.05 (0.71 –1.58)
	DM	1.35 (0.92–1.97)	0.427
	Non-DM	1.15 (0.82–1.61)
CVM/HHF	CAD	0.98 (0.78–1.24)	0.052
	Non-CAD	1.29 (0.96–1.72)
	DM	1.07 (0.82–1.40)	0.862
	Non-DM	1.11 (0.87–1.43)
1-month troponin I
ACM	CAD	2.12 (1.47–3.07)	0.009
	Non-CAD	0.96 (0.59–1.57)
	DM	1.79 (1.16–2.77)	0.456
	Non-DM	1.43 (0.96–2.14)
CVM/HHF	CAD	1.41 (1.09–1.83)	0.1 93
	Non-CAD	1.07 (0.76–1.51)
	DM	1.31 (0.97–1.78)	0.787
	Non-DM	1.24 (0.93 –1.65)

ACM, all-cause mortality; CAD, coronary artery disease; CI, confidence interval; CVM/HHF, cardiovascular mortality or hospitalization for heart failure; DM, diabetes mellitus; HR, hazard ratio.

Data represent interaction P values from multivariate analysis. Covariates included in the multivariate model: age, gender, race, geographic region, ischaemic heart failure aetiology, New York Heart Association class III/IV, ejection fraction, systolic blood pressure, heart rate, NT-proBNP level, serum sodium, blood urea nitrogen, serum creatinine, QRS duration, aliskiren randomization, past medical history (prior HHF, coronary artery disease, atrial fibrillation, diabetes, chronic obstructive pulmonary disease), and medications (ACEI/ARB, beta-blocker, mineralocorticoid receptor antagonist, digoxin, implantable cardioverter-defibrillator, cardiac resynchronization therapy).